Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response

Sunday, December 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the potential of Class-A cams to induce cell death via HBV core protein aggregation. This mechanism may also activate the innate immune response, suggesting a promising avenue for therapeutic development in chronic HBV infections. The findings could pave the way for innovative treatments targeting HBV.
Price reaction · baseline $17.5275 (2023-12-01 close) · 3 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Class-A cams show potential in inducing cell death.
  • Research may activate the innate immune response.
  • Findings could lead to new therapeutic strategies for HBV.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What are Class-A cams?

Class-A cams are compounds studied for their ability to induce cell death in HBV-infected cells.

How do Class-A cams affect HBV?

They induce cell death through HBV core protein aggregation and may activate the innate immune response.

What is the significance of this research?

The findings could lead to new therapeutic strategies for treating chronic HBV infections.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare HBV cell death innate immune response therapeutic strategies
Last updated: Dec 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →